Articles about immunotherapy

Fred Hutch study: Mangling RNA may extend use of immunotherapy drugs

Experimental compounds that alter RNA boost the effectiveness of immunotherapy drugs against cancer cells and could potentially extend their use… Read More

Researchers create synthetic proteins that use logic to choose which cells to kill

The age of molecular-scale computing is entering a new era, thanks to the development of a system that uses synthetic… Read More

Celularity and Infectious Disease Research Institute will try out COVID-19 cell therapy

Seattle’s Infectious Disease Research Institute and a New Jersey company called Celularity have been cleared by the Food and Drug… Read More

Thin metal films loaded with immune cells show promise as cancer therapy

Researchers at Seattle’s Fred Hutchinson Cancer Research Center have demonstrated the effectiveness of a new method for getting immune cells… Read More

Seattle Children’s opens a ‘cure factory’ to explore treatments for childhood cancer and other diseases

Maryn Sage remembers the words she heard on the day she learned that her 16-year-old son, Jedd Feliciano, was cancer-free.… Read More

Merck research chief Roger Perlmutter touts Seattle biotech strength after $300M Immune Design deal

Two months after Merck acquired Seattle-based biotech Immune Design for $300 million, the president of Merck Research Laboratories, Roger Perlmutter,… Read More

Drug giant Merck pays $300M to acquire Seattle biotech company Immune Design

Merck, one of the world’s largest drugmakers, agreed to buy Seattle-based biotechnology company Immune Design for $300 million in cash.… Read More

Bristol-Myers Squibb’s $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert

Things are a little on edge in Seattle’s biotech scene after the Jan. 3 announcement that pharmaceutical giant Bristol-Myers Squibb… Read More

Year in Science: Genetic breakthroughs make dreams (and nightmares) come true

In science, it was the best of times, and the worst of times. 2018 was a year when researchers focused… Read More

Biotech startup Kineta inks cancer deal with Pfizer worth up to $505M

Seattle-based biotech startup Kineta today received a leg-up in its efforts to kill cancerous tumors using the immune system. Kineta announced an… Read More

Allen Institute launches new immunology division with $125M from its late founder

Billionaire philanthropist Paul Allen died two months ago, but before he passed away, he passed along a $125 million commitment… Read More

Celgene CEO: Treating cancer is becoming ‘ironically easy’ — now the problem is affordability

BELLEVUE, Wash. — Cancer treatments have improved astronomically in the past few decades. But as more patients overcome the disease,… Read More

Fred Hutch study discovers how cancer evades immunotherapies, sometimes returning years later

Few advances in cancer treatment have gotten as much attention in the past decade as immunotherapies, therapies that use the… Read More

OncoResponse raises $40M to start clinical trials of antibody-based cancer immunotherapies

OncoResponse, a Seattle biotech company creating antibody-based treatments for cancer, has raised a $40 million Series B round to advance… Read More

Groundbreaking study of cancer-killing immunotherapy could reduce side effects and improve performance

The emerging form of cancer treatment called CAR T immunotherapy is wiping out the disease in some terminal patients — but… Read More

Podcast

How this cancer therapy went from scientific underdog to potential cure

Nearly 40 years ago, scientists had what seemed like a crazy idea: What if we could reprogram cancer patients’ immune… Read More

Seattle Children’s launches into solid tumor treatments with new CAR T immunotherapy trial

Seattle Children’s Research Institute is launching a clinical trial that will examine a new kind of cancer-fighting treatment. The treatment… Read More

Fred Hutch study: Nanoparticles could help cutting-edge therapies get inside solid tumors

CAR T immunotherapies are one of the hottest topics of research — and investment — in the world of medicine today. The emerging… Read More

Startup Aminex Therapeutics raises $10M, begins clinical trials of immunotherapy treatment

Seattle startup Aminex Therapeutics announced $10 million in new funding Wednesday, alongside the first clinical trial of its immunotherapy drug.… Read More

Seattle Children’s aims to cure terminal brain cancer using immunotherapy with new BrainChild initiative

When Avery Berg was diagnosed with aggressive, late-stage brain cancer at just 10 years old, she fought hard to stay… Read More

Seattle Children’s launches CureWorks, a project aimed at revolutionizing cancer treatment for kids

New cancer immunotherapies could revolutionize how we treat the disease, but for many children, those treatments are far out of… Read More

Portland immunotherapy startup tops $10M in funding as it launches first clinical trial

In 2008, Emmanuel Akporiaye left a tenured position at the University of Arizona to move across the country and launch… Read More

Longtime Juno Therapeutics CEO Hans Bishop leaves role after acquisition by Celgene

Hans Bishop, the co-founder and longtime CEO of immunotherapy company Juno Therapeutics, has quietly left that role following the company’s… Read More

Cell therapies are giving Seattle an edge in biotech, driving three acquisitions in under a month

On a chilly Monday morning in January, Seattle awoke to the news that one of its most promising companies, Juno… Read More

Pittsburgh research giants unveil landmark $200M immunotherapy center to combat cancer and aging

PITTSBURGH — Far before humans understood the basics of modern medicine, our immune systems protected our bodies from microscopic invaders… Read More

Seattle Genetics to acquire Cascadian Therapeutics for $614M to further bolster its cancer fight

Seattle Genetics, a biotechnology company that develops antibody-based cancer treatments, announced Wednesday that it will acquire Cascadian Therapeutics and the… Read More

Why Celgene decided to buy Juno Therapeutics for $9B — with a little help from U.S. tax reform

When Celgene announced Monday that it will acquire Seattle-based biotech Juno Therapeutics for $9 billion, the development was a surprise… Read More

Juno Therapeutics stock surges 50% as Celgene is reportedly in talks to buy the company

New Jersey-based biotech giant Celgene is in talks to buy Seattle-based biotech Juno Therapeutics, according to a report in the… Read More

Study finds differences between adult and childhood leukemia, calls for developing age-specific cancer treatments

A study conducted by Fred Hutchinson Cancer Research Center, with contributions from researchers across North America, has found stark differences… Read More

Seattle Genetics COO taking the reins at stealthy biotech startup Silverback Therapeutics

Eric Dobmeier, the longtime COO at public biotech company Seattle Genetics, is stepping down from his role to become CEO… Read More